Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero
Shares of Viking Therapeutics, Genfit, and Sagimet Biosciences rose significantly following news that Novo Nordisk is acquiring Akero Therapeutics. This acquisition, valued at $11.5 billion, highlights the increasing interest in therapies for metabolic dysfunction-associated steatohepatitis (MASH), benefiting other companies in the MASH drug development space.
Behavioral Patterns of AKRO and Institutional Flows
This article from Stock Traders Daily discusses the behavioral patterns of Akero Therapeutics Inc. (NASDAQ: AKRO) and institutional flows. It highlights three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles. The piece also mentions support and resistance signals and offers real-time analysis through AI integration for subscribers.
(AKRO) Movement Within Algorithmic Entry Frameworks
This article from Stock Traders Daily discusses Akero Therapeutics Inc. (NASDAQ: AKRO) within their algorithmic entry frameworks. It highlights key findings and signals generated by their AI models for trading strategies and multi-timeframe analysis. The piece also promotes access to real-time signals and personalized alerts for subscribers.
Akero Therapeutics shareholders approve Novo Nordisk merger
Akero Therapeutics shareholders have approved the merger with Novo Nordisk. This approval is a significant step towards the completion of the acquisition, allowing Novo Nordisk to proceed with integrating Akero into its operations.
Q4 Activity Finishes Off Stronger Biopharma M&A Year In 2025
The biopharma sector concluded 2025 with a stronger mergers and acquisitions trend in Q4 compared to 2024, according to data from Evaluate Pharma. This indicates an improved year for M&A activity in the biopharmaceutical industry. The article highlights the financial performance of the sector at the end of the year.
Akero Therapeutics, Inc. (AKRO) Stock Analysis: Navigating the Biotech’s 3.39% Potential Upside
Akero Therapeutics, Inc. (AKRO) is a biotechnology company attracting attention with its lead product candidate, efruxifermin (EFX), for metabolic dysfunction-associated steatohepatitis (MASH). The company has a market cap of $4.5 billion and its stock is trading near its 52-week high, although financial metrics reflect an investment-heavy development phase. Strategic partnerships, like the one with Amgen Inc., and analyst ratings indicating a modest upside, highlight Akero's potential for investors willing to undertake the inherent risks of biotech.
Alkeon Capital Management LLC Grows Stake in Akero Therapeutics, Inc. $AKRO
Alkeon Capital Management LLC increased its stake in Akero Therapeutics, Inc. by 19.3% in the second quarter, now owning 1,850,934 shares valued at $98.8 million. Despite this, company insiders, including the COO and CEO, sold 55,000 shares worth $2.79 million, reducing insider ownership to 7.07%. Akero Therapeutics has a "Hold" consensus rating with an average target price of $73.38, having recently missed quarterly EPS expectations and faced several analyst downgrades.
Frazier Life Sciences Management L.P. Acquires New Shares in Akero Therapeutics, Inc. $AKRO
Frazier Life Sciences Management L.P. has acquired a new position of 366,784 shares in Akero Therapeutics, valued at approximately $19.57 million, making it their 27th-largest holding. Despite significant institutional investment, company insiders have sold 55,000 shares, and analysts have downgraded the stock to a "Hold" rating with a target price of $73.38, following a reported EPS miss in the last quarter.
Hudson Bay Capital Management LP Buys 84,573 Shares of Akero Therapeutics, Inc. $AKRO
Hudson Bay Capital Management LP increased its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) by 28% in Q2, acquiring an additional 84,573 shares to hold a total of 386,523 shares valued at $20.63 million. This comes despite significant insider selling, with the COO and CEO offloading 42,500 shares totaling approximately $2.2 million over the last 90 days. The stock currently trades at $54.65, with analysts maintaining a "Hold" consensus rating and an average target price of $73.38.
General Atlantic L.P. Acquires 500,000 Shares of Akero Therapeutics, Inc. $AKRO
General Atlantic L.P. increased its stake in Akero Therapeutics, Inc. by purchasing an additional 500,000 shares, bringing its total ownership to 5,733,989 shares and making it the firm's fifth-largest holding. Other institutional investors also increased their positions, yet analyst sentiment has cooled with several downgrades to a consensus "Hold" rating. Insiders, notably CEO Andrew Cheng and COO Jonathan Young, have sold a significant number of shares, indicating a mixed outlook for the stock.
Liver Fibrosis Market Expected to Gain Momentum Through 2034, According to DelveInsight | Madrigal Pharma, Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio
The Liver Fibrosis market is projected to reach approximately USD 1,800 million in 2023 and is expected to grow significantly by 2034, driven by increasing prevalence of chronic liver diseases, advancements in diagnostics, and novel drug development. Key pharmaceutical companies like Madrigal Pharmaceuticals and Akero Therapeutics are leading the development of new therapies, with recent approvals and promising clinical trial results for treatments such as Rezdiffra and efruxifermin. DelveInsight's report provides an in-depth analysis of market trends, epidemiology, and emerging therapies across the 7MM (United States, EU4, UK, and Japan).
Liver Fibrosis Market Expected to Gain Momentum Through 2034, According to DelveInsight | Madrigal Pharma, Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio
The liver fibrosis market is projected to grow significantly through 2034, driven by an increasing prevalence of chronic liver diseases, advancements in diagnostics, and ongoing drug development. Key companies including Madrigal Pharmaceuticals and Akero Therapeutics are developing therapies, with REZDIFFRA (resmetirom) projected to reach a market value of around USD 2,500 million in the 7MM by 2034. The US leads in liver fibrosis cases, and new treatments for metabolic dysfunction-associated steatohepatitis (MASH) and advanced liver fibrosis are rapidly progressing through clinical trials.
HighVista Strategies LLC Acquires 35,926 Shares of Akero Therapeutics, Inc. $AKRO
HighVista Strategies LLC increased its stake in Akero Therapeutics by 149.3% in Q2, acquiring an additional 35,926 shares to hold 59,993 shares, representing about 0.08% of Akero. Despite this, insiders have been net sellers, divesting 55,000 shares in the last 90 days. The stock currently trades around $54.65, and analysts maintain a consensus "Hold" rating with an average price target of $73.38.
Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from S&P Biotechnology Select Industry Index
Akero Therapeutics, Inc. (NasdaqGS:AKRO) has been dropped from the S&P Biotechnology Select Industry Index. This news follows several other announcements, including its removal from the S&P Global BMI Index and S&P TMI Index, and the completed acquisition of Akero Therapeutics by Novo Nordisk A/S. Akero Therapeutics is a clinical-stage company focusing on treatments for serious metabolic diseases like MASH.
Stempoint Capital LP Reduces Stock Position in Akero Therapeutics, Inc. $AKRO
Stempoint Capital LP significantly reduced its stake in Akero Therapeutics ($AKRO) by 25.2% in Q2 2025, selling 39,406 shares and now holding 116,779 shares valued at $6.23 million. This comes as company insiders, including COO Jonathan Young, have also been net sellers of the stock. Akero Therapeutics currently trades around $54.65 with a "Hold" consensus rating from Wall Street analysts, who have an average target price of $73.38.
Akero Therapeutics Announces Board and Executive Changes Following Merger
Akero Therapeutics, Inc. announced significant changes to its board and executive team on December 9, 2025, following the consummation of a merger. All previous directors and executive officers resigned, and new appointments were made in accordance with the merger agreement. These changes were detailed in an SEC Form 8-K filing.
Vivo Capital LLC Buys 233,521 Shares of Akero Therapeutics, Inc. $AKRO
Vivo Capital LLC significantly increased its stake in Akero Therapeutics (NASDAQ:AKRO) by 116.1%, acquiring an additional 233,521 shares to hold a total of 434,689 shares valued at approximately $23.2 million. This move comes as several analysts have downgraded the stock to "Hold" with an average target price of $73.38, and company insiders have been net sellers, offloading shares worth about $4.27 million in the past 90 days. Akero Therapeutics is currently developing efruxifermin (EFX) for metabolic dysfunction-associated steatohepatitis (MASH).
Novo Nordisk has completed its acquisition of Akero Therapeutics
Novo Nordisk has officially completed its acquisition of Akero Therapeutics, paying $54 per share in cash and a Contingent Value Right for an additional $6 per share upon US regulatory approval of Akero's lead candidate EFX. This transaction, initially announced on October 9, 2025, integrates Akero, a clinical-stage company specializing in metabolic diseases like MASH, into Novo Nordisk as a wholly-owned subsidiary, leading to Akero's delisting from Nasdaq. The acquisition aims to advance treatments for serious chronic diseases, leveraging Akero's ongoing Phase 3 clinical studies for efruxifermin (EFX).
(AKRO) Risk Channels and Responsive Allocation
This article provides an analysis of Akero Therapeutics Inc. (NASDAQ: AKRO), indicating a neutral near and mid-term outlook but a positive long-term bias. It outlines institutional trading strategies including long, breakout, and short setups, along with multi-timeframe signal analysis suggesting resistance testing. The analysis highlights an exceptional 47.4:1 risk-reward short setup.
JPMorgan Chase & Co. Sells 18,890 Shares of Akero Therapeutics, Inc. $AKRO
JPMorgan Chase & Co. significantly reduced its stake in Akero Therapeutics ($AKRO) by 5.7% in the second quarter, selling 18,890 shares but still owning 313,493 shares valued at approximately $16.73 million. This comes as other institutional investors have reshuffled their positions, with some increasing holdings and others opening new multi-million dollar stakes. The company faces increased scrutiny with lowered analyst ratings to a "Hold" consensus and recent insider selling activity.
Novo Nordisk wins German approval to buy Akero Therapeutics
The German competition authority has approved Novo Nordisk's acquisition of Akero Therapeutics. The Bundeskartellamt reviewed the deal based on the transaction-value threshold and found no expected restriction on innovation-based competition. This approval allows Novo Nordisk to proceed with its acquisition of Akero Therapeutics.
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO
Kahn Swick & Foti, LLC (KSF), led by former Louisiana Attorney General Charles C. Foti, Jr., is investigating the proposed sale of Akero Therapeutics, Inc. (NasdaqGS: AKRO) to Novo Nordisk A/S. Shareholders are set to receive $54.00 per share in cash plus a Contingent Value Right for an additional $6.00 per share upon full U.S. regulatory approval of efruxifermin by June 30, 2031. KSF is assessing whether this consideration and the sale process adequately value the company, encouraging concerned shareholders to contact them regarding their legal rights.
Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025
Akero Therapeutics announced new findings from its Phase 2b SYMMETRY and HARMONY trials for efruxifermin, showing antifibrotic effects and potential to reduce disease progression in patients with MASH-related cirrhosis. These post-hoc analyses, presented at The Liver Meeting® 2025, reinforce efruxifermin's ability to improve non-invasive measures of fibrosis and validate previously observed improvements through AI-assisted digital pathology. The results support the ongoing Phase 3 clinical trial program for efruxifermin in treating serious metabolic diseases.
Assessing Akero Therapeutics (AKRO) Valuation After Strong Share Price Gains - Yahoo Finance
Akero Therapeutics (AKRO) has seen significant share price appreciation, with a 72% increase over the past year and a 92% year-to-date return, outperforming many biotech peers. The article examines whether the stock's current price-to-book ratio of 4.2x is justified, noting it's above the industry average but below its closest peers, suggesting a balanced market view of its risks and potential. Investors are encouraged to consider the company's valuation in light of its pipeline and growth prospects.
Understanding Momentum Shifts in (AKRO)
This article analyzes Akero Therapeutics Inc. (NASDAQ: AKRO) using AI models, highlighting strong sentiment, a significant risk-reward setup, and current signals. It details three institutional trading strategies tailored for different risk profiles and provides a multi-timeframe signal analysis for near-term, mid-term, and long-term horizons.
Akero Therapeutics Inc. (AKRO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
This article provides live stock quotes and charts for Akero Therapeutics Inc. (AKRO), showing its current stock price and daily change. It also includes sections for analyst ratings, which are currently N/A with no analyst coverage in the last three months, and indicates that earnings information for the company is not currently available.
Akero Therapeutics CEO Cheng sells $1.62m in shares By Investing.com - Investing.com Canada
This article reports on the sale of Akero Therapeutics CEO Andrew Cheng's shares totaling $1.62 million. The transaction highlights insider activity within the company. Further details of the sale are not provided in the given content.
Akero Therapeutics CEO Cheng sells $1.62m in shares By Investing.com - Investing.com India
The article reports that William Cheng, CEO of Akero Therapeutics (NASDAQ: AKRO), sold shares worth $1.62 million. Due to an application error, the full details of the transaction are not available in the provided content.
Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio - Zenopa
Novo Nordisk announced its definitive agreement to acquire Akero Therapeutics to expand its MASH portfolio with Akero's phase 3 FGF21 analogue, efruxifermin (EFX). This acquisition aligns with Novo Nordisk's strategy to treat diabetes, obesity, and associated comorbidities, as EFX has shown potential to reverse liver damage and is in late-stage clinical trials for MASH. The deal involves an initial cash payment of $4.7 billion, with a potential additional payment of $0.5 billion based on regulatory approval.
StockWatch: Novo Nordisk Raises MASH Bet with Up-to-$5.2B Akero Acquisition - Genetic Engineering and Biotechnology News
Novo Nordisk is acquiring Akero Therapeutics for up to $5.2 billion to strengthen its metabolic dysfunction-associated steatohepatitis (MASH) pipeline with Akero's lead FGF21 analog, efruxifermin (EFX). This acquisition follows rival Roche's move into the MASH market and positions Novo Nordisk to compete with other developers like Madrigal Pharmaceuticals and GSK. The article also highlights recent surges in gene editing stocks, driven by positive clinical data from Intellia Therapeutics.
TD Cowen Downgrades Akero Therapeutics to Hold From Buy, Adjusts Price Target to $58 From $76 - MarketScreener
TD Cowen has downgraded Akero Therapeutics to Hold from Buy and reduced its price target to $58 from $76. This downgrade follows other analyst adjustments, including Wolfe Research and HC Wainwright, and occurs amidst news of Novo Nordisk's acquisition of Akero Therapeutics.
Novo Nordisk to acquire Akero Therapeutics for up to USD 5.2 billion - Medical Dialogues
Novo Nordisk announced its intention to acquire Akero Therapeutics for up to $5.2 billion, aiming to strengthen its position in treating metabolic dysfunction-associated steatohepatitis (MASH). The acquisition focuses on Akero's FGF21 analogue efruxifermin (EFX), a promising treatment for MASH, especially given its links to diabetes and obesity, areas of expertise for Novo Nordisk. The deal, expected to close by year-end, involves an initial payment of $54 per share and a potential additional $6 per share upon US regulatory approval of EFX for compensated cirrhosis due to MASH.
Wolfe Research Downgrades Akero Therapeutics (NASDAQ:AKRO) to Hold - Defense World
Wolfe Research has downgraded Akero Therapeutics (NASDAQ:AKRO) from an "outperform" to a "hold" rating. This follows a similar downgrade by Jefferies Financial Group, which also cut its price target for AKRO. The article also details recent insider activity and institutional investor holdings in Akero Therapeutics.
Akero Therapeutics (NASDAQ:AKRO) Rating Lowered to “Hold” at HC Wainwright - Defense World
HC Wainwright downgraded Akero Therapeutics (NASDAQ:AKRO) from a "buy" to a "hold" rating following a similar action by Canaccord Genuity Group, which also reduced its price target from $73.00 to $54.00. The article details recent insider activity and institutional changes in holdings, with several firms increasing their positions in Akero Therapeutics during the first quarter. Akero Therapeutics is developing efruxifermin (EFX) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Novo Nordisk Is Buying Akero Therapeutics. It’s More Good News for Biotech Stocks.
Novo Nordisk announced one of the largest biotech acquisitions of the year, purchasing Akero Therapeutics. This deal is expected to intensify Novo Nordisk's competition with Eli Lilly and is seen as positive news for the broader biotech sector. The article also notes a recent change in Novo Nordisk's CEO.
Novo Nordisk To Acquire Akero Therapeutics; Akero Shareholders To Receive $54/Shr, CVR Of $6/Shr
Novo Nordisk has announced a definitive agreement to acquire Akero Therapeutics, a clinical-stage company focusing on treatments for serious metabolic diseases. The deal involves Novo Nordisk acquiring all outstanding shares of Akero for $54 per share in cash, totaling $4.7 billion, plus a potential additional payment of $6 per share upon U.S. regulatory approval of EFX for compensated cirrhosis due to MASH. This acquisition is expected to increase Novo Nordisk's R&D costs in 2026, leading to an estimated 3% point negative impact on full-year operating profit growth, while not affecting the 2025 outlook.
Novo Nordisk to buy Akero for up to $5.2 billion in new CEO's revival push
Novo Nordisk announced its acquisition of U.S.-based Akero Therapeutics for up to $5.2 billion to secure a promising late-stage liver disease drug candidate, efruxifermin. This is the first major move by new CEO Mike Doustdar, who aims to focus on new obesity and diabetes drugs that also treat cardiometabolic conditions like MASH, while addressing market share losses to Eli Lilly and preparing for semaglutide's loss of exclusivity. The deal, which includes an upfront cash payment and potential additional payments, is expected to close by year-end.
Shareholder Alert: The Ademi Firm investigates whether Akero Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
The Ademi Firm is investigating Akero Therapeutics Inc. (NASDAQ: AKRO) regarding potential breaches of fiduciary duty related to its transaction with Novo Nordisk. Shareholders are set to receive $54.00 per share, plus a contingent value right for an additional $6.00 if Akero's drug efruxifermin gains U.S. regulatory approval by June 30, 2031. The investigation focuses on whether the Akero board is fulfilling its duties to shareholders, especially in light of the significant penalty clause for competing bids.
Novo in $5.2 Billion Deal for Liver Disease Drugmaker Akero
Novo Nordisk A/S has agreed to acquire Akero Therapeutics Inc. for up to $5.2 billion to strengthen its presence in the liver disease market, particularly conditions linked to obesity. The deal includes an upfront cash payment of $4.7 billion ($54 per share), representing a 16% premium over Akero's recent closing price, with an additional $500 million contingent on regulatory achievements. This acquisition highlights Novo's strategic expansion into treatments beyond its core diabetes and weight-loss drugs.
Novo inks Akero buyout worth up to $5.2B to bag late-phase MASH prospect
Novo Nordisk has agreed to acquire Akero Therapeutics for up to $5.2 billion to gain a late-phase metabolic dysfunction-associated steatohepatitis (MASH) prospect, efruxifermin (EFX). This acquisition positions Novo Nordisk in a competitive MASH market, where it will face rivals like Roche and Madrigal Pharmaceuticals. The deal includes an upfront payment and a contingent value right based on regulatory approval of EFX, which Novo anticipates will be a cornerstone therapy.
Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion
Akero Therapeutics (Nasdaq: AKRO) has announced its acquisition by Novo Nordisk A/S for up to $5.2 billion. Akero shareholders will receive $54.00 per share in cash at closing and a Contingent Value Right of $6.00 per share upon U.S. regulatory approval of efruxifermin (EFX) for MASH by June 30, 2031, representing significant premiums to Akero's recent stock prices. This acquisition aims to accelerate the development and commercialization of Akero's lead candidate, EFX, a treatment for metabolic dysfunction-associated steatohepatitis (MASH), leveraging Novo Nordisk's expertise in cardio-metabolic diseases.
Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio
Novo Nordisk announced its acquisition of Akero Therapeutics for $4.7 billion in cash at closing, plus a contingent value right of $0.5 billion. This acquisition brings Akero's FGF21 analogue, efruxifermin (EFX), a potential first-in-class treatment for MASH, to Novo Nordisk's portfolio. EFX is currently in Phase 3 development and has shown significant fibrosis regression in Phase 2 trials, aligning with Novo Nordisk's strategy to expand its metabolic disease treatments.
Novo Nordisk to buy Akero Therapeutics for up to $5.2 billion
Novo Nordisk has agreed to acquire Akero Therapeutics for up to $5.2 billion, gaining access to Akero's experimental liver disease drug, efruxifermin. The drug is currently being studied for the treatment of severe scarring or cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH). The acquisition involves an upfront cash payment per share and an additional payment contingent on the drug's full U.S. approval by June 30, 2031.
Latham Wins Dismissal With Prejudice for Pioneering Liver-Disease Drug Company Akero Therapeutics
Latham & Watkins LLP secured a dismissal with prejudice in a securities class action against Akero Therapeutics, Inc., a company developing drugs for liver diseases. The lawsuit alleged that Akero misled investors regarding the patient population in a Phase 2b study for a new drug. The court granted the dismissal due to the plaintiffs' failure to adequately allege scienter, stating that knowledge alone is insufficient without particularized facts of intent to defraud.
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Akero Therapeutics reported its second quarter 2025 financial results, highlighting the publication of Phase 2b SYMMETRY trial results in the New England Journal of Medicine and multiple presentations at EASL Congress 2025. The company announced strong financial standing with $1,086.2 million in cash, cash equivalents, and marketable securities, sufficient to fund operations into 2028. Akero also provided updates on its EFX clinical program, emphasizing its potential in reversing compensated cirrhosis due to MASH and consistent fibrosis improvement in pre-cirrhotic MASH.
Akero Therapeutics Announces Proposed Public Offering of Common Stock
Akero Therapeutics announced a proposed underwritten public offering of $300.0 million of its common stock, with an option for underwriters to purchase an additional $45.0 million. The offering is subject to market conditions and will be managed by J.P. Morgan, Morgan Stanley, and Jefferies as joint book-running managers. The clinical-stage company is developing treatments for serious metabolic diseases, including MASH, with its lead product candidate efruxifermin (EFX) currently in Phase 3 clinical studies.
Akero Therapeutics nearly doubles stock price on positive clinical studies
Akero Therapeutics' stock price nearly doubled after announcing positive Phase 2b clinical trial results for its drug efruxifermin (EFX) in treating MASH patients with compensated cirrhosis. The study showed significant cirrhosis reversal in patients treated with EFX, with good tolerability and an improving effect over time. This offers a promising new treatment option for MASH, a more severe form of MASLD, currently with limited effective therapies for cirrhotic patients.
Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
Akero Therapeutics has dosed the first patient in its Phase 3 SYNCHRONY Outcomes study, evaluating efruxifermin (EFX) for compensated cirrhosis due to MASH. This trial is part of a broader SYNCHRONY program aimed at addressing various stages of MASH severity and seeking marketing applications for both pre-cirrhotic liver fibrosis and compensated cirrhosis. EFX is an Fc-FGF21 fusion protein designed to improve liver health and metabolic dysregulation, with data from the Phase 2b SYMMETRY study for compensated cirrhosis expected in Q1 2025.
Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Akero Therapeutics (Nasdaq: AKRO) reported its Q2 2024 financial results, highlighted by the initiation of the Phase 3 SYNCHRONY Outcomes trial for efruxifermin (EFX) and promising 96-week data from the Phase 2b HARMONY study. The company maintained a strong cash position of $848.3 million, expected to fund operations into the second half of 2027, despite increased R&D and operating expenses. The report also detailed leadership changes and updates on ongoing clinical trials for EFX in MASH patients.
AKERO ALERT: Bragar Eagel & Squire, P.C. Announces that a
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Akero Therapeutics, Inc. (NASDAQ: AKRO) on behalf of investors who purchased stock between September 13, 2022, and October 9, 2023. The lawsuit alleges that Akero made false and misleading statements regarding its SYMMETRY clinical trial for efruxifermin (EFX) in NASH patients, specifically concerning patient enrollment criteria and the trial's alignment with FDA guidance. Investors suffered substantial losses when the truth was revealed, causing Akero's stock to plummet by nearly 70%.
